,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'Clinician application received.', 'fs': 'Clinician application received.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQk2AM'}, 'Id': 'a0POZ0000033FQk2AM', 'Event_Date__c': '2016-11-24', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Clinician application received.', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArE6QAK'}, 'change': None}]",Nov 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'Discussed during the creation of the first Hospital Medicines List.    &#39;The Subcommittee considered that further information was needed before making a recommendation on levamisole. The Subcommittee requested feedback from ID physicians on the indications for which it is used, and whether there should be any restrictions around its use.&#39;', 'fs': 'Discussed during the creation of the first Hospital Medicines List.    &#39;The Subcommittee considered that further information was needed before making a recommendation on levamisole. The Subcommittee requested feedback from ID physicians on the indications for which it is used, and whether there should be any restrictions around its use.&#39;', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2011', 'fs': 'Jun 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQd2AM'}, 'Id': 'a0POZ0000033FQd2AM', 'Event_Date__c': '2011-06-07', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'Discussed during the creation of the first Hospital Medicines List.    &#39;The Subcommittee considered that further information was needed before making a recommendation on levamisole. The Subcommittee requested feedback from ID physicians on the indications for which it is used, and whether there should be any restrictions around its use.&#39;', 'Formatted_Date__c': 'Jun 2011', 'Status_History__c': 'a132P000000AppcQAC'}, 'change': None}, {'Summary': {'s': '&#39;The Subcommittee noted that it had previously deferred making a recommendation in relation to levamisole, and noted the feedback in relation to this. The Subcommittee recommended that PHARMAC seek a view on the need for this from Renal Physicians.&#39;', 'fs': '&#39;The Subcommittee noted that it had previously deferred making a recommendation in relation to levamisole, and noted the feedback in relation to this. The Subcommittee recommended that PHARMAC seek a view on the need for this from Renal Physicians.&#39;', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2012', 'fs': 'Jun 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 June 2012.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 June 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQe2AM'}, 'Id': 'a0POZ0000033FQe2AM', 'Event_Date__c': '2012-06-05', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 June 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': '&#39;The Subcommittee noted that it had previously deferred making a recommendation in relation to levamisole, and noted the feedback in relation to this. The Subcommittee recommended that PHARMAC seek a view on the need for this from Renal Physicians.&#39;', 'Formatted_Date__c': 'Jun 2012', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Aq3HQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQf2AM'}, 'Id': 'a0POZ0000033FQf2AM', 'Event_Date__c': '2012-08-02', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq5JQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQg2AM'}, 'Id': 'a0POZ0000033FQg2AM', 'Event_Date__c': '2012-08-02', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq6AQAS'}, 'change': None}, {'Summary': {'s': '&#39;The Subcommittee noted that levamisole is an effective treatment for frequent relapsing steroid sensitive nephrotic syndrome but it had been withdrawn from the market worldwide due to serious side-effects including agranulocytosis. The Subcommittee noted that consideration for funding for this treatment could be considered on a case-by-case basis through NPPA.&#39;', 'fs': '&#39;The Subcommittee noted that levamisole is an effective treatment for frequent relapsing steroid sensitive nephrotic syndrome but it had been withdrawn from the market worldwide due to serious side-effects including agranulocytosis. The Subcommittee noted that consideration for funding for this treatment could be considered on a case-by-case basis through NPPA.&#39;', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2014', 'fs': 'Dec 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQj2AM'}, 'Id': 'a0POZ0000033FQj2AM', 'Event_Date__c': '2014-12-02', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': '&#39;The Subcommittee noted that levamisole is an effective treatment for frequent relapsing steroid sensitive nephrotic syndrome but it had been withdrawn from the market worldwide due to serious side-effects including agranulocytosis. The Subcommittee noted that consideration for funding for this treatment could be considered on a case-by-case basis through NPPA.&#39;', 'Formatted_Date__c': 'Dec 2014', 'Status_History__c': 'a132P000000AqqcQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQl2AM'}, 'Id': 'a0POZ0000033FQl2AM', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArExQAK'}, 'change': None}, {'Summary': {'s': 'Levamisole was recommended for the treatment of frequently relapsing steroid sensitive nephrotic syndrome (FR SSNS) in paediatric patients with a low priority if a suitable supply was obtained.', 'fs': 'Levamisole was recommended for the treatment of frequently relapsing steroid sensitive nephrotic syndrome (FR SSNS) in paediatric patients with a low priority if a suitable supply was obtained.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQm2AM'}, 'Id': 'a0POZ0000033FQm2AM', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'Outcome__c': 'Low', 'Summary__c': 'Levamisole was recommended for the treatment of frequently relapsing steroid sensitive nephrotic syndrome (FR SSNS) in paediatric patients with a low priority if a suitable supply was obtained.', 'Formatted_Date__c': 'Dec 2016', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ArEyQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2017', 'fs': 'Aug 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQo2AM'}, 'Id': 'a0POZ0000033FQo2AM', 'Event_Date__c': '2017-08-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Aug 2017', 'Status_History__c': 'a132P000000ArJzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2018', 'fs': 'Jul 2018', 'change': None}, 'Event_Description': {'s': 'No supplier currently identified.', 'fs': 'No supplier currently identified.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQp2AM'}, 'Id': 'a0POZ0000033FQp2AM', 'Event_Date__c': '2018-07-01', 'Event_Description__c': 'No supplier currently identified.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2018', 'Status_History__c': 'a132P000000ArUGQA0'}, 'change': None}]",Jun 2011,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQn2AM'}, 'Id': 'a0POZ0000033FQn2AM', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArEzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQq2AM'}, 'Id': 'a0POZ0000033FQq2AM', 'Event_Date__c': '2023-07-05', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000F6qJQAS'}, 'change': None}]",Dec 2016,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': 'Levamisole was not included in the first edition of the HML. This does not prevent applications for this product being considered.', 'fs': 'Levamisole was not included in the first edition of the HML. This does not prevent applications for this product being considered.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2013', 'fs': 'Jul 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQi2AM'}, 'Id': 'a0POZ0000033FQi2AM', 'Event_Date__c': '2013-07-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Summary__c': 'Levamisole was not included in the first edition of the HML. This does not prevent applications for this product being considered.', 'Formatted_Date__c': 'Jul 2013', 'Status_History__c': 'a132P000000AqQuQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQr2AM'}, 'Id': 'a0POZ0000033FQr2AM', 'Event_Date__c': '2023-07-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000FC9bQAG'}, 'change': None}]",Jul 2013,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2012', 'fs': 'Sep 2012', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQh2AM'}, 'Id': 'a0POZ0000033FQh2AM', 'Event_Date__c': '2012-09-25', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Sep 2012', 'Status_History__c': 'a132P000000Aq8kQAC'}, 'change': None}, {'Summary': {'s': '<p>We are proposing to decline this application as we\xa0<span style=""color: rgb(68, 68, 68);"">understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration. </span></p>', 'fs': '<p>We are proposing to decline this application as we\xa0<span style=""color: rgb(68, 68, 68);"">understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration. </span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQs2AM'}, 'Id': 'a0POZ0000033FQs2AM', 'Event_Date__c': '2023-08-01', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'Summary__c': '<p>We are proposing to decline this application as we\xa0<span style=""color: rgb(68, 68, 68);"">understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration. </span></p>', 'Formatted_Date__c': 'Aug 2023', 'Status_History__c': 'a13OZ0000019ZsVYAU'}, 'change': None}]",Sep 2012,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': 'The consultation document proposed not be listed levamisole in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'fs': 'The consultation document proposed not be listed levamisole in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQt2AM'}, 'Id': 'a0POZ0000033FQt2AM', 'Event_Date__c': '2023-09-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'Summary__c': 'The consultation document proposed not be listed levamisole in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a132P000000AqBEQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQv2AM'}, 'Id': 'a0POZ0000033FQv2AM', 'Event_Date__c': '2023-12-13', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004YfEXYA0'}, 'change': None}]",Sep 2023,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033FQu2AM'}, 'Id': 'a0POZ0000033FQu2AM', 'Event_Date__c': '2023-11-07', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000004YZM7YAO'}, 'change': None}]",Nov 2023,False,True
